Abstract
Objective: Adropin, a newly identified regulatory protein has garnered attention given its potential role in metabolism regulation, especially glucose metabolism and insulin resistance. However, studies on the association between adropin and type 2 diabetes mellitus (T2DM) are equivocal. The aim of this study is to assess the association between serum adropin levels and T2DM using a systematic review and meta-analysis of observational studies. Methods: PubMed, Scopus, ISI Web of science, and Google Scholar were searched, up to August 2022, for studies that reported the association between serum levels of adropin in adults with T2DM compared to a control group without diabetes. A random-effect model was used to compute the pooled weighted mean difference (WMD) with 95% confidence intervals (CI). Results: Meta-analysis of 15 studies (n = 2813 participants) revealed that the serum adropin concentrations were significantly lower in patients with T2DM compared with the control group (WMD= -0.60 ng/mL, 95% CI: -0.70 to -0.49; I2 = 99.5%). Subgroup analysis also found lower concentration of adropin in patients with T2DM who were otherwise healthy compared to a control group (n = 9; WMD=-0.04 ng/ml, 95% CI= -0.06 to -0.01, p = 0.002; I2 = 96.4). Conclusions: Our study showed adropin levels are lower in patients with diabetes compared to a control group without diabetes. However, the limitations of observational studies challenge the validity of the results, and further investigations are needed to confirm the veracity of these findings and additionally explore possible mechanisms.
| Original language | English |
|---|---|
| Article number | 73 |
| Number of pages | 11 |
| Journal | BMC Endocrine Disorders |
| Volume | 23 |
| Issue number | 1 |
| Early online date | 7 Apr 2023 |
| DOIs | |
| Publication status | E-pub ahead of print - 7 Apr 2023 |
Bibliographical note
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Funder
We sincerely thank Dr. Andrew Butler for all valuable comments and suggestions, which helped us to improve the quality of the article. Authors would like to thank the electronic library of Shahid Sadoughi University of Medical Sciences to allow our group for performing more comprehensive search.Funding Information:
This work was funded by the North Khorasan University of Medical Sciences. The financial source had no role in the design of the study, described data management, analysis, reporting of study results, or decision to submit the manuscript for publication.
Publisher Copyright:
© 2023, The Author(s).
Keywords
- Adropin
- Type 2 diabetes
- Systematic review
- Meta-analysis
- Observational studies
